Table of Contents
3 - 6 മാസത്തേക്കുള്ള മികച്ച മ്യൂച്വൽ ഫണ്ട്
3 മുതൽ 6 മാസം വരെയുള്ള ചെറിയ കാലയളവിലേക്ക്, നിങ്ങൾക്ക് ഒന്നുകിൽ നിങ്ങളുടെ പണം പാർക്ക് ചെയ്യാംലിക്വിഡ് മ്യൂച്വൽ ഫണ്ടുകൾ അല്ലെങ്കിൽ അൾട്രാ ഷോർട്ട് ടേംകടം മ്യൂച്വൽ ഫണ്ട്. ദ്രാവകമ്യൂച്വൽ ഫണ്ടുകൾ സാധാരണയായി ഗവൺമെന്റ് സെക്യൂരിറ്റികളിലും 3 മാസം വരെയുള്ള നിക്ഷേപ സർട്ടിഫിക്കറ്റുകളിലും നിക്ഷേപിക്കുക.
എന്നിരുന്നാലും ഉയർന്ന റിട്ടേണുകൾക്കായി റിസ്ക് എടുക്കാൻ ഒരാൾ ഉത്സുകനാണെങ്കിൽ ചുവടെയുള്ള കുറച്ച് ഓപ്ഷനുകൾ നോക്കാം
3 മാസത്തെ മികച്ച 5 മ്യൂച്വൽ ഫണ്ടുകൾ
ഇവയുടെ ലിസ്റ്റ് ചുവടെയുണ്ട്മികച്ച മ്യൂച്വൽ ഫണ്ടുകൾ മൊത്തം ആസ്തി കഴിഞ്ഞു100 കോടി കൂടാതെ കഴിഞ്ഞ 3 മാസങ്ങളിൽ മികച്ച വരുമാനം നൽകി.
The Investment objective of the Scheme is to provide investors with the opportunities for long-term capital appreciation by investing in a diversified portfolio of Equity and Equity related Instruments across market capitalization. However there can be no assurance that the investment objective under the Scheme will be realized IDBI Diversified Equity Fund is a Equity - Multi Cap fund was launched on 28 Mar 14. It is a fund with Moderately High risk and has given a Below is the key information for IDBI Diversified Equity Fund Returns up to 1 year are on The Scheme will seek to invest predominantly in a diversified portfolio of equity and equity related instruments with the objective to provide investors with opportunities for capital appreciation and income along with the benefit of income-tax deduction(under section 80C of the Income-tax Act, 1961) on their investments. Investments in this scheme would be subject to a statutory lock-in of 3 years from the date of allotment to be eligible for income-tax benefits under Section 80C. There can be no assurance that the investment objective under the scheme will be realized. IDBI Equity Advantage Fund is a Equity - ELSS fund was launched on 10 Sep 13. It is a fund with Moderately High risk and has given a Below is the key information for IDBI Equity Advantage Fund Returns up to 1 year are on The Investment objective of the Scheme is to provide investors with the opportunities for long-term capital appreciation by investing predominantly in Equity and Equity related Instruments of Large Cap companies. However
there can be no assurance that the investment objective under the Scheme will be realized. IDBI India Top 100 Equity Fund is a Equity - Large Cap fund was launched on 15 May 12. It is a fund with Moderately High risk and has given a Below is the key information for IDBI India Top 100 Equity Fund Returns up to 1 year are on The investment objective of the scheme is to invest in the stocks and equity related instruments comprising the S&P CNX Nifty Index in the same weights as these stocks represented in the Index with the intent to replicate the performance of the Total Returns Index of S&P CNX Nifty index. The scheme will adopt a passive investment strategy and will seek to achieve the investment objective by minimizing the tracking error between the S&P CNX Nifty index (Total Returns Index) and the scheme. IDBI Nifty Index Fund is a Others - Index Fund fund was launched on 25 Jun 10. It is a fund with Moderately High risk and has given a Below is the key information for IDBI Nifty Index Fund Returns up to 1 year are on (Erstwhile IDBI Prudence Fund) The investment objective of the scheme would be to generate opportunities for capital appreciation along with income by investing in a diversified basket of equity and equity related instruments, debt and money market instruments. However, there can be no assurance that the investment objective of the scheme will be realized. IDBI Hybrid Equity Fund is a Hybrid - Hybrid Equity fund was launched on 24 Oct 16. It is a fund with Moderately High risk and has given a Below is the key information for IDBI Hybrid Equity Fund Returns up to 1 year are on 1. IDBI Diversified Equity Fund
CAGR/Annualized return of 15.4% since its launch. Ranked 56 in Multi Cap category. . IDBI Diversified Equity Fund
Growth Launch Date 28 Mar 14 NAV (28 Jul 23) ₹37.99 ↑ 0.14 (0.37 %) Net Assets (Cr) ₹382 on 30 Jun 23 Category Equity - Multi Cap AMC IDBI Asset Management Limited Rating ☆☆ Risk Moderately High Expense Ratio 2.46 Sharpe Ratio 1.01 Information Ratio -0.53 Alpha Ratio -1.07 Min Investment 5,000 Min SIP Investment 500 Exit Load 0-1 Years (1%),1 Years and above(NIL) Growth of 10,000 investment over the years.
Date Value 31 Dec 19 ₹10,000 31 Dec 20 ₹11,618 31 Dec 21 ₹15,872 31 Dec 22 ₹15,696 Returns for IDBI Diversified Equity Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 28 Jul 23 Duration Returns 1 Month 2.4% 3 Month 10.2% 6 Month 13.2% 1 Year 13.5% 3 Year 22.7% 5 Year 12% 10 Year 15 Year Since launch 15.4% Historical performance (Yearly) on absolute basis
Year Returns 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Fund Manager information for IDBI Diversified Equity Fund
Name Since Tenure Data below for IDBI Diversified Equity Fund as on 30 Jun 23
Equity Sector Allocation
Sector Value Asset Allocation
Asset Class Value Top Securities Holdings / Portfolio
Name Holding Value Quantity 2. IDBI Equity Advantage Fund
CAGR/Annualized return of 16% since its launch. Ranked 21 in ELSS category. . IDBI Equity Advantage Fund
Growth Launch Date 10 Sep 13 NAV (28 Jul 23) ₹43.39 ↑ 0.04 (0.09 %) Net Assets (Cr) ₹485 on 30 Jun 23 Category Equity - ELSS AMC IDBI Asset Management Limited Rating ☆☆☆ Risk Moderately High Expense Ratio 2.39 Sharpe Ratio 1.21 Information Ratio -1.13 Alpha Ratio 1.78 Min Investment 500 Min SIP Investment 500 Exit Load NIL Growth of 10,000 investment over the years.
Date Value 31 Dec 19 ₹10,000 31 Dec 20 ₹10,837 31 Dec 21 ₹13,609 31 Dec 22 ₹13,903 Returns for IDBI Equity Advantage Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 28 Jul 23 Duration Returns 1 Month 3.1% 3 Month 9.7% 6 Month 15.1% 1 Year 16.9% 3 Year 20.8% 5 Year 10% 10 Year 15 Year Since launch 16% Historical performance (Yearly) on absolute basis
Year Returns 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Fund Manager information for IDBI Equity Advantage Fund
Name Since Tenure Data below for IDBI Equity Advantage Fund as on 30 Jun 23
Equity Sector Allocation
Sector Value Asset Allocation
Asset Class Value Top Securities Holdings / Portfolio
Name Holding Value Quantity 3. IDBI India Top 100 Equity Fund
CAGR/Annualized return of 14.2% since its launch. Ranked 45 in Large Cap category. . IDBI India Top 100 Equity Fund
Growth Launch Date 15 May 12 NAV (28 Jul 23) ₹44.16 ↑ 0.05 (0.11 %) Net Assets (Cr) ₹655 on 30 Jun 23 Category Equity - Large Cap AMC IDBI Asset Management Limited Rating ☆☆☆ Risk Moderately High Expense Ratio 2.47 Sharpe Ratio 1.09 Information Ratio 0.14 Alpha Ratio 2.11 Min Investment 5,000 Min SIP Investment 500 Exit Load 0-1 Years (1%),1 Years and above(NIL) Growth of 10,000 investment over the years.
Date Value 31 Dec 19 ₹10,000 31 Dec 20 ₹11,643 31 Dec 21 ₹15,281 31 Dec 22 ₹15,730 Returns for IDBI India Top 100 Equity Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 28 Jul 23 Duration Returns 1 Month 3% 3 Month 9.2% 6 Month 12.5% 1 Year 15.4% 3 Year 21.9% 5 Year 12.6% 10 Year 15 Year Since launch 14.2% Historical performance (Yearly) on absolute basis
Year Returns 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Fund Manager information for IDBI India Top 100 Equity Fund
Name Since Tenure Data below for IDBI India Top 100 Equity Fund as on 30 Jun 23
Equity Sector Allocation
Sector Value Asset Allocation
Asset Class Value Top Securities Holdings / Portfolio
Name Holding Value Quantity 4. IDBI Nifty Index Fund
CAGR/Annualized return of 10.3% since its launch. Ranked 83 in Index Fund category. . IDBI Nifty Index Fund
Growth Launch Date 25 Jun 10 NAV (28 Jul 23) ₹36.2111 ↓ -0.02 (-0.06 %) Net Assets (Cr) ₹208 on 30 Jun 23 Category Others - Index Fund AMC IDBI Asset Management Limited Rating ☆ Risk Moderately High Expense Ratio 0.9 Sharpe Ratio 1.04 Information Ratio -3.93 Alpha Ratio -1.03 Min Investment 5,000 Min SIP Investment 500 Exit Load NIL Growth of 10,000 investment over the years.
Date Value 31 Dec 19 ₹10,000 31 Dec 20 ₹11,465 31 Dec 21 ₹14,158 31 Dec 22 ₹14,825 Returns for IDBI Nifty Index Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 28 Jul 23 Duration Returns 1 Month 3.7% 3 Month 9.1% 6 Month 11.9% 1 Year 16.2% 3 Year 20.3% 5 Year 11.7% 10 Year 15 Year Since launch 10.3% Historical performance (Yearly) on absolute basis
Year Returns 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Fund Manager information for IDBI Nifty Index Fund
Name Since Tenure Data below for IDBI Nifty Index Fund as on 30 Jun 23
Asset Allocation
Asset Class Value Top Securities Holdings / Portfolio
Name Holding Value Quantity 5. IDBI Hybrid Equity Fund
CAGR/Annualized return of 8.3% since its launch. . IDBI Hybrid Equity Fund
Growth Launch Date 24 Oct 16 NAV (28 Jul 23) ₹17.1253 ↓ -0.01 (-0.05 %) Net Assets (Cr) ₹179 on 30 Jun 23 Category Hybrid - Hybrid Equity AMC IDBI Asset Management Limited Rating Risk Moderately High Expense Ratio 2.52 Sharpe Ratio 1.03 Information Ratio -1.03 Alpha Ratio -0.26 Min Investment 5,000 Min SIP Investment 500 Exit Load NIL Growth of 10,000 investment over the years.
Date Value 31 Dec 19 ₹10,000 31 Dec 20 ₹11,699 31 Dec 21 ₹14,146 31 Dec 22 ₹14,031 Returns for IDBI Hybrid Equity Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 28 Jul 23 Duration Returns 1 Month 2.1% 3 Month 7.8% 6 Month 9.8% 1 Year 12.1% 3 Year 14.4% 5 Year 7.1% 10 Year 15 Year Since launch 8.3% Historical performance (Yearly) on absolute basis
Year Returns 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Fund Manager information for IDBI Hybrid Equity Fund
Name Since Tenure Data below for IDBI Hybrid Equity Fund as on 30 Jun 23
Asset Allocation
Asset Class Value Equity Sector Allocation
Sector Value Debt Sector Allocation
Sector Value Credit Quality
Rating Value Top Securities Holdings / Portfolio
Name Holding Value Quantity
6 മാസത്തെ മികച്ച 5 മ്യൂച്വൽ ഫണ്ടുകൾ
മൊത്തം ആസ്തിയുള്ള മികച്ച മ്യൂച്വൽ ഫണ്ടുകളുടെ ലിസ്റ്റ് ചുവടെയുണ്ട്100 കോടി കൂടാതെ കഴിഞ്ഞ 6 മാസങ്ങളിൽ മികച്ച വരുമാനം നൽകി.
(Erstwhile SBI Pharma Fund) To provide the investors maximum growth opportunity through equity
investments in stocks of growth oriented sectors of the economy. SBI Healthcare Opportunities Fund is a Equity - Sectoral fund was launched on 31 Dec 04. It is a fund with High risk and has given a Below is the key information for SBI Healthcare Opportunities Fund Returns up to 1 year are on (Erstwhile UTI Pharma & Healthcare Fund) The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors. UTI Healthcare Fund is a Equity - Sectoral fund was launched on 28 Jun 99. It is a fund with High risk and has given a Below is the key information for UTI Healthcare Fund Returns up to 1 year are on (Erstwhile L&T India Special Situations Fund) To generate long-term capital growth from a diversified portfolio of predominantly equity and equity related securities including equity derivatives. L&T Large and Midcap Fund is a Equity - Large & Mid Cap fund was launched on 22 May 06. It is a fund with Moderately High risk and has given a Below is the key information for L&T Large and Midcap Fund Returns up to 1 year are on To generate long-term capital appreciation from a diversified portfolio of predominantly equity and equity related securities, including equity derivatives, in the Indian markets. The Scheme will predominantly invest in large cap stocks. The Scheme could also additionally invest in Foreign Securities. L&T India Large Cap Fund is a Equity - Large Cap fund was launched on 23 Oct 07. It is a fund with Moderately High risk and has given a Below is the key information for L&T India Large Cap Fund Returns up to 1 year are on The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns. TATA India Pharma & Healthcare Fund is a Equity - Sectoral fund was launched on 28 Dec 15. It is a fund with High risk and has given a Below is the key information for TATA India Pharma & Healthcare Fund Returns up to 1 year are on 1. SBI Healthcare Opportunities Fund
CAGR/Annualized return of 16.1% since its launch. Ranked 34 in Sectoral category. Return for 2024 was 42.2% , 2023 was 38.2% and 2022 was -6% . SBI Healthcare Opportunities Fund
Growth Launch Date 31 Dec 04 NAV (08 Jan 25) ₹441.232 ↓ -2.06 (-0.46 %) Net Assets (Cr) ₹3,460 on 30 Nov 24 Category Equity - Sectoral AMC SBI Funds Management Private Limited Rating ☆☆ Risk High Expense Ratio 2.09 Sharpe Ratio 2.85 Information Ratio 0.75 Alpha Ratio 5.08 Min Investment 5,000 Min SIP Investment 500 Exit Load 0-15 Days (0.5%),15 Days and above(NIL) Growth of 10,000 investment over the years.
Date Value 31 Dec 19 ₹10,000 31 Dec 20 ₹16,583 31 Dec 21 ₹19,925 31 Dec 22 ₹18,725 31 Dec 23 ₹25,885 31 Dec 24 ₹36,814 Returns for SBI Healthcare Opportunities Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 8 Jan 25 Duration Returns 1 Month 2.3% 3 Month 5.4% 6 Month 21.5% 1 Year 40.2% 3 Year 24.3% 5 Year 30% 10 Year 15 Year Since launch 16.1% Historical performance (Yearly) on absolute basis
Year Returns 2023 42.2% 2022 38.2% 2021 -6% 2020 20.1% 2019 65.8% 2018 -0.5% 2017 -9.9% 2016 2.1% 2015 -14% 2014 27.1% Fund Manager information for SBI Healthcare Opportunities Fund
Name Since Tenure Tanmaya Desai 1 Jun 11 13.6 Yr. Pradeep Kesavan 31 Dec 23 1.01 Yr. Data below for SBI Healthcare Opportunities Fund as on 30 Nov 24
Equity Sector Allocation
Sector Value Health Care 89.92% Basic Materials 6.58% Asset Allocation
Asset Class Value Cash 3.5% Equity 96.5% Top Securities Holdings / Portfolio
Name Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Dec 17 | SUNPHARMA13% ₹445 Cr 2,500,000
↑ 100,000 Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB6% ₹222 Cr 360,000 Cipla Ltd (Healthcare)
Equity, Since 31 Aug 16 | CIPLA6% ₹196 Cr 1,280,000
↑ 280,000 Max Healthcare Institute Ltd Ordinary Shares (Healthcare)
Equity, Since 31 Mar 21 | MAXHEALTH6% ₹196 Cr 2,000,000
↓ -100,000 Lupin Ltd (Healthcare)
Equity, Since 31 Aug 23 | LUPIN5% ₹164 Cr 800,000 Lonza Group Ltd ADR (Healthcare)
Equity, Since 31 Jan 24 | LZAGY4% ₹152 Cr 300,000 Poly Medicure Ltd (Healthcare)
Equity, Since 31 Aug 24 | POLYMED4% ₹139 Cr 500,000
↓ -140,000 Krishna Institute of Medical Sciences Ltd (Healthcare)
Equity, Since 30 Nov 22 | 5433084% ₹130 Cr 2,200,000
↓ -300,000 Jupiter Life Line Hospitals Ltd (Healthcare)
Equity, Since 31 Aug 23 | JLHL4% ₹126 Cr 832,871
↓ -67,129 Aether Industries Ltd (Basic Materials)
Equity, Since 31 May 22 | 5435343% ₹115 Cr 1,400,000 2. UTI Healthcare Fund
CAGR/Annualized return of 15.4% since its launch. Ranked 40 in Sectoral category. Return for 2024 was 42.9% , 2023 was 38.2% and 2022 was -12.3% . UTI Healthcare Fund
Growth Launch Date 28 Jun 99 NAV (09 Jan 25) ₹290.943 ↓ -2.72 (-0.92 %) Net Assets (Cr) ₹1,203 on 30 Nov 24 Category Equity - Sectoral AMC UTI Asset Management Company Ltd Rating ☆ Risk High Expense Ratio 2.38 Sharpe Ratio 2.43 Information Ratio 0.1 Alpha Ratio 0.54 Min Investment 5,000 Min SIP Investment 500 Exit Load 0-1 Years (1%),1 Years and above(NIL) Growth of 10,000 investment over the years.
Date Value 31 Dec 19 ₹10,000 31 Dec 20 ₹16,736 31 Dec 21 ₹19,930 31 Dec 22 ₹17,475 31 Dec 23 ₹24,150 31 Dec 24 ₹34,500 Returns for UTI Healthcare Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 8 Jan 25 Duration Returns 1 Month 0.3% 3 Month -0.5% 6 Month 19.3% 1 Year 38% 3 Year 20.6% 5 Year 27.6% 10 Year 15 Year Since launch 15.4% Historical performance (Yearly) on absolute basis
Year Returns 2023 42.9% 2022 38.2% 2021 -12.3% 2020 19.1% 2019 67.4% 2018 1.2% 2017 -7.5% 2016 6.2% 2015 -9.7% 2014 12.4% Fund Manager information for UTI Healthcare Fund
Name Since Tenure Kamal Gada 2 May 22 2.67 Yr. Data below for UTI Healthcare Fund as on 30 Nov 24
Equity Sector Allocation
Sector Value Health Care 96.03% Basic Materials 1.27% Financial Services 0.29% Asset Allocation
Asset Class Value Cash 2.41% Equity 97.59% Top Securities Holdings / Portfolio
Name Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 06 | SUNPHARMA11% ₹129 Cr 725,000 Cipla Ltd (Healthcare)
Equity, Since 31 Jan 03 | CIPLA6% ₹69 Cr 450,660 Ajanta Pharma Ltd (Healthcare)
Equity, Since 31 Jul 17 | AJANTPHARM5% ₹58 Cr 193,047
↓ -15,318 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 28 Feb 18 | DRREDDY5% ₹57 Cr 470,234
↑ 34,734 Glenmark Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Mar 24 | GLENMARK4% ₹47 Cr 309,311
↑ 58,980 Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLAND4% ₹46 Cr 266,306 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Apr 21 | APOLLOHOSP3% ₹41 Cr 60,000 Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Dec 20 | FORTIS3% ₹40 Cr 611,658
↓ -22,787 Procter & Gamble Health Ltd (Healthcare)
Equity, Since 31 Dec 20 | PGHL3% ₹38 Cr 74,000 Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLAB3% ₹38 Cr 61,480 3. L&T Large and Midcap Fund
CAGR/Annualized return of 12.8% since its launch. Ranked 32 in Large & Mid Cap category. . L&T Large and Midcap Fund
Growth Launch Date 22 May 06 NAV (25 Nov 22) ₹72.8402 ↑ 0.12 (0.16 %) Net Assets (Cr) ₹1,620 on 31 Oct 22 Category Equity - Large & Mid Cap AMC L&T Investment Management Ltd Rating ☆☆☆ Risk Moderately High Expense Ratio 2.25 Sharpe Ratio 0.14 Information Ratio -0.76 Alpha Ratio 1.28 Min Investment 5,000 Min SIP Investment 500 Exit Load 0-1 Years (1%),1 Years and above(NIL) Growth of 10,000 investment over the years.
Date Value 31 Dec 19 ₹10,000 31 Dec 20 ₹11,468 31 Dec 21 ₹14,941 Returns for L&T Large and Midcap Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 8 Jan 25 Duration Returns 1 Month 0.4% 3 Month 3.7% 6 Month 18% 1 Year 1.5% 3 Year 14.9% 5 Year 7.9% 10 Year 15 Year Since launch 12.8% Historical performance (Yearly) on absolute basis
Year Returns 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Fund Manager information for L&T Large and Midcap Fund
Name Since Tenure Data below for L&T Large and Midcap Fund as on 31 Oct 22
Equity Sector Allocation
Sector Value Asset Allocation
Asset Class Value Top Securities Holdings / Portfolio
Name Holding Value Quantity 4. L&T India Large Cap Fund
CAGR/Annualized return of 10% since its launch. Ranked 56 in Large Cap category. . L&T India Large Cap Fund
Growth Launch Date 23 Oct 07 NAV (25 Nov 22) ₹42.242 ↑ 0.02 (0.04 %) Net Assets (Cr) ₹758 on 31 Oct 22 Category Equity - Large Cap AMC L&T Investment Management Ltd Rating ☆☆☆ Risk Moderately High Expense Ratio 2.48 Sharpe Ratio -0.1 Information Ratio -1.05 Alpha Ratio -2.34 Min Investment 5,000 Min SIP Investment 500 Exit Load 0-1 Years (1%),1 Years and above(NIL) Growth of 10,000 investment over the years.
Date Value 31 Dec 19 ₹10,000 31 Dec 20 ₹11,306 31 Dec 21 ₹14,076 Returns for L&T India Large Cap Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 8 Jan 25 Duration Returns 1 Month 2.1% 3 Month 4.4% 6 Month 16.7% 1 Year 2.9% 3 Year 13.6% 5 Year 10.5% 10 Year 15 Year Since launch 10% Historical performance (Yearly) on absolute basis
Year Returns 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Fund Manager information for L&T India Large Cap Fund
Name Since Tenure Data below for L&T India Large Cap Fund as on 31 Oct 22
Equity Sector Allocation
Sector Value Asset Allocation
Asset Class Value Top Securities Holdings / Portfolio
Name Holding Value Quantity 5. TATA India Pharma & Healthcare Fund
CAGR/Annualized return of 13.5% since its launch. Return for 2024 was 40.4% , 2023 was 36.6% and 2022 was -8% . TATA India Pharma & Healthcare Fund
Growth Launch Date 28 Dec 15 NAV (09 Jan 25) ₹31.211 ↓ -0.23 (-0.73 %) Net Assets (Cr) ₹1,214 on 30 Nov 24 Category Equity - Sectoral AMC Tata Asset Management Limited Rating Risk High Expense Ratio 0 Sharpe Ratio 2.17 Information Ratio 0.55 Alpha Ratio 4.58 Min Investment 5,000 Min SIP Investment 150 Exit Load 0-3 Months (0.25%),3 Months and above(NIL) Growth of 10,000 investment over the years.
Date Value 31 Dec 19 ₹10,000 31 Dec 20 ₹16,438 31 Dec 21 ₹19,572 31 Dec 22 ₹17,998 31 Dec 23 ₹24,582 31 Dec 24 ₹34,513 Returns for TATA India Pharma & Healthcare Fund
absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 8 Jan 25 Duration Returns 1 Month 2.1% 3 Month 1.1% 6 Month 16.2% 1 Year 36.2% 3 Year 21.1% 5 Year 27.8% 10 Year 15 Year Since launch 13.5% Historical performance (Yearly) on absolute basis
Year Returns 2023 40.4% 2022 36.6% 2021 -8% 2020 19.1% 2019 64.4% 2018 5.5% 2017 -2.6% 2016 4.7% 2015 -14.7% 2014 Fund Manager information for TATA India Pharma & Healthcare Fund
Name Since Tenure Meeta Shetty 9 Mar 21 3.82 Yr. Rajat Srivastava 16 Sep 24 0.29 Yr. Data below for TATA India Pharma & Healthcare Fund as on 30 Nov 24
Equity Sector Allocation
Sector Value Health Care 93.55% Basic Materials 2.17% Asset Allocation
Asset Class Value Cash 4.28% Equity 95.72% Top Securities Holdings / Portfolio
Name Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Jan 16 | SUNPHARMA12% ₹143 Cr 804,300 Aurobindo Pharma Ltd (Healthcare)
Equity, Since 30 Apr 20 | AUROPHARMA8% ₹94 Cr 741,000 Lupin Ltd (Healthcare)
Equity, Since 30 Nov 17 | LUPIN7% ₹84 Cr 410,240 Cipla Ltd (Healthcare)
Equity, Since 30 Apr 20 | CIPLA6% ₹75 Cr 490,000 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 18 | DRREDDY6% ₹74 Cr 614,555 Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLAB5% ₹65 Cr 104,965 Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Oct 20 | FORTIS5% ₹56 Cr 855,100 Zydus Lifesciences Ltd (Healthcare)
Equity, Since 31 Dec 22 | ZYDUSLIFE4% ₹46 Cr 471,287 Alkem Laboratories Ltd (Healthcare)
Equity, Since 31 Aug 20 | ALKEM3% ₹42 Cr 75,249 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 31 Dec 16 | APOLLOHOSP3% ₹40 Cr 58,903
മ്യൂച്വൽ ഫണ്ടുകളിൽ ഓൺലൈനിൽ എങ്ങനെ നിക്ഷേപിക്കാം?
Fincash.com-ൽ ആജീവനാന്ത സൗജന്യ നിക്ഷേപ അക്കൗണ്ട് തുറക്കുക.
നിങ്ങളുടെ രജിസ്ട്രേഷനും KYC പ്രക്രിയയും പൂർത്തിയാക്കുക
രേഖകൾ അപ്‌ലോഡ് ചെയ്യുക (പാൻ, ആധാർ മുതലായവ).കൂടാതെ, നിങ്ങൾ നിക്ഷേപിക്കാൻ തയ്യാറാണ്!
ഇവിടെ നൽകിയിരിക്കുന്ന വിവരങ്ങൾ കൃത്യമാണെന്ന് ഉറപ്പാക്കാൻ എല്ലാ ശ്രമങ്ങളും നടത്തിയിട്ടുണ്ട്. എന്നിരുന്നാലും, ഡാറ്റയുടെ കൃത്യത സംബന്ധിച്ച് യാതൊരു ഉറപ്പും നൽകുന്നില്ല. എന്തെങ്കിലും നിക്ഷേപം നടത്തുന്നതിന് മുമ്പ് സ്കീം വിവര രേഖ ഉപയോഗിച്ച് പരിശോധിക്കുക.
AMFI Registration No. 112358 | CIN: U74999MH2016PTC282153
Shepard Technologies Pvt. Ltd. (with ARN code 112358) makes no warranties or representations, express or implied, on products offered through the platform. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Terms and conditions of the website are applicable.
©2025 Shepard Technologies Private Limited. All Rights Reserved